{"id":870,"date":"2026-03-12T17:26:34","date_gmt":"2026-03-12T16:26:34","guid":{"rendered":"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/?page_id=870"},"modified":"2026-03-13T18:14:09","modified_gmt":"2026-03-13T17:14:09","slug":"5-des-etudes-portant-sur-quelques-malades-phase-ii","status":"publish","type":"page","link":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/sujets\/genese-dun-medicament\/5-des-etudes-portant-sur-quelques-malades-phase-ii\/","title":{"rendered":"5. Des \u00e9tudes portant sur quelques malades: phase II"},"content":{"rendered":"\n<p>Si un nouveau produit ne fait appara\u00eetre aucun effet ind\u00e9sirable notable chez des sujets sains, on l&rsquo;administre aussi pour la premi\u00e8re fois \u00e0 des malades. De mani\u00e8re g\u00e9n\u00e9rale, 100 \u00e0 500 patients re\u00e7oivent alors soit le nouveau m\u00e9dicament, soit le produit qui constituait jusqu&rsquo;alors la r\u00e9f\u00e9rence. Dans d&rsquo;autres cas, un groupe re\u00e7oit le nouveau m\u00e9dicament et l&rsquo;autre un traitement sans principe actif, appel\u00e9 \u00abplacebo\u00bb. A partir de ces \u00e9tudes, les chercheurs peuvent analyser si &#8211; et dans l&rsquo;affirmative, dans quelle mesure &#8211; le nouveau m\u00e9dicament s&rsquo;av\u00e8re sup\u00e9rieur au traitement habituel. Il s&rsquo;agit non seulement de savoir si un m\u00e9dicament est efficace, mais \u00e9galement comment il est tol\u00e9r\u00e9 et quelle dose est la mieux adapt\u00e9e et m\u00e9nage le plus les patients. On \u00e9tudie aussi quelles transformations chimiques le principe actif subit dans l&rsquo;organisme. Si l&rsquo;on observe des effets ind\u00e9sirables inacceptables, le traitement est imm\u00e9diatement interrompu. Les effets ind\u00e9sirables sont souvent la raison qui motive l&rsquo;arr\u00eat total du d\u00e9veloppement d&rsquo;un m\u00e9dicament. Les \u00e9tudes de phase II durent entre 6 mois et un an.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"http:\/\/biotechlerncenter.interpharma.ch\/wp-content\/uploads\/sites\/4\/2020\/01\/istock_klinische-studie_900.jpg\" alt=\"\" class=\"wp-image-3510\"\/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Si un nouveau produit ne fait appara\u00eetre aucun effet ind\u00e9sirable notable chez des sujets sains, on l&rsquo;administre aussi pour la premi\u00e8re fois \u00e0 des malades. De mani\u00e8re g\u00e9n\u00e9rale, 100 \u00e0 500 patients re\u00e7oivent alors soit le nouveau m\u00e9dicament, soit le produit qui constituait jusqu&rsquo;alors la r\u00e9f\u00e9rence. Dans d&rsquo;autres cas, un groupe re\u00e7oit le nouveau m\u00e9dicament [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":898,"menu_order":4,"comment_status":"closed","ping_status":"closed","template":"page-templates\/unterthema.php","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-870","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>5. Des \u00e9tudes portant sur quelques malades: phase II - biotechlerncenter<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/biotechlerncenter.interpharma.ch\/themen\/wie-ein-medikament-entsteht\/5-studien-mit-wenigen-kranken-phase-ii\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"5. Des \u00e9tudes portant sur quelques malades: phase II\" \/>\n<meta property=\"og:description\" content=\"Si un nouveau produit ne fait appara\u00eetre aucun effet ind\u00e9sirable notable chez des sujets sains, on l&rsquo;administre aussi pour la premi\u00e8re fois \u00e0 des malades. De mani\u00e8re g\u00e9n\u00e9rale, 100 \u00e0 500 patients re\u00e7oivent alors soit le nouveau m\u00e9dicament, soit le produit qui constituait jusqu&rsquo;alors la r\u00e9f\u00e9rence. Dans d&rsquo;autres cas, un groupe re\u00e7oit le nouveau m\u00e9dicament [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/biotechlerncenter.interpharma.ch\/themen\/wie-ein-medikament-entsteht\/5-studien-mit-wenigen-kranken-phase-ii\/\" \/>\n<meta property=\"og:site_name\" content=\"biotechlerncenter\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-13T17:14:09+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/biotechlerncenter.interpharma.ch\/wp-content\/uploads\/sites\/4\/2020\/01\/istock_klinische-studie_900.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/biotechlerncenter.interpharma.ch\/themen\/wie-ein-medikament-entsteht\/5-studien-mit-wenigen-kranken-phase-ii\/\",\"url\":\"https:\/\/biotechlerncenter.interpharma.ch\/themen\/wie-ein-medikament-entsteht\/5-studien-mit-wenigen-kranken-phase-ii\/\",\"name\":\"5. Des \u00e9tudes portant sur quelques malades: phase II - biotechlerncenter\",\"isPartOf\":{\"@id\":\"https:\/\/biotechlerncenter.interpharma.ch\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/biotechlerncenter.interpharma.ch\/themen\/wie-ein-medikament-entsteht\/5-studien-mit-wenigen-kranken-phase-ii\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/biotechlerncenter.interpharma.ch\/themen\/wie-ein-medikament-entsteht\/5-studien-mit-wenigen-kranken-phase-ii\/#primaryimage\"},\"thumbnailUrl\":\"http:\/\/biotechlerncenter.interpharma.ch\/wp-content\/uploads\/sites\/4\/2020\/01\/istock_klinische-studie_900.jpg\",\"datePublished\":\"2026-03-12T16:26:34+00:00\",\"dateModified\":\"2026-03-13T17:14:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/biotechlerncenter.interpharma.ch\/themen\/wie-ein-medikament-entsteht\/5-studien-mit-wenigen-kranken-phase-ii\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/biotechlerncenter.interpharma.ch\/themen\/wie-ein-medikament-entsteht\/5-studien-mit-wenigen-kranken-phase-ii\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/biotechlerncenter.interpharma.ch\/themen\/wie-ein-medikament-entsteht\/5-studien-mit-wenigen-kranken-phase-ii\/#primaryimage\",\"url\":\"http:\/\/biotechlerncenter.interpharma.ch\/wp-content\/uploads\/sites\/4\/2020\/01\/istock_klinische-studie_900.jpg\",\"contentUrl\":\"http:\/\/biotechlerncenter.interpharma.ch\/wp-content\/uploads\/sites\/4\/2020\/01\/istock_klinische-studie_900.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/biotechlerncenter.interpharma.ch\/themen\/wie-ein-medikament-entsteht\/5-studien-mit-wenigen-kranken-phase-ii\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\/\/biotechlerncenter.interpharma.ch\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sujets\",\"item\":\"https:\/\/biotechlerncenter.interpharma.ch\/fr\/sujets\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Gen\u00e8se d&rsquo;un m\u00e9dicament\",\"item\":\"https:\/\/biotechlerncenter.interpharma.ch\/fr\/sujets\/genese-dun-medicament\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"5. Des \u00e9tudes portant sur quelques malades: phase II\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/biotechlerncenter.interpharma.ch\/#website\",\"url\":\"https:\/\/biotechlerncenter.interpharma.ch\/\",\"name\":\"biotechlerncenter\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/biotechlerncenter.interpharma.ch\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"5. Des \u00e9tudes portant sur quelques malades: phase II - biotechlerncenter","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/biotechlerncenter.interpharma.ch\/themen\/wie-ein-medikament-entsteht\/5-studien-mit-wenigen-kranken-phase-ii\/","og_locale":"fr_FR","og_type":"article","og_title":"5. Des \u00e9tudes portant sur quelques malades: phase II","og_description":"Si un nouveau produit ne fait appara\u00eetre aucun effet ind\u00e9sirable notable chez des sujets sains, on l&rsquo;administre aussi pour la premi\u00e8re fois \u00e0 des malades. De mani\u00e8re g\u00e9n\u00e9rale, 100 \u00e0 500 patients re\u00e7oivent alors soit le nouveau m\u00e9dicament, soit le produit qui constituait jusqu&rsquo;alors la r\u00e9f\u00e9rence. Dans d&rsquo;autres cas, un groupe re\u00e7oit le nouveau m\u00e9dicament [&hellip;]","og_url":"https:\/\/biotechlerncenter.interpharma.ch\/themen\/wie-ein-medikament-entsteht\/5-studien-mit-wenigen-kranken-phase-ii\/","og_site_name":"biotechlerncenter","article_modified_time":"2026-03-13T17:14:09+00:00","og_image":[{"url":"http:\/\/biotechlerncenter.interpharma.ch\/wp-content\/uploads\/sites\/4\/2020\/01\/istock_klinische-studie_900.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/biotechlerncenter.interpharma.ch\/themen\/wie-ein-medikament-entsteht\/5-studien-mit-wenigen-kranken-phase-ii\/","url":"https:\/\/biotechlerncenter.interpharma.ch\/themen\/wie-ein-medikament-entsteht\/5-studien-mit-wenigen-kranken-phase-ii\/","name":"5. Des \u00e9tudes portant sur quelques malades: phase II - biotechlerncenter","isPartOf":{"@id":"https:\/\/biotechlerncenter.interpharma.ch\/#website"},"primaryImageOfPage":{"@id":"https:\/\/biotechlerncenter.interpharma.ch\/themen\/wie-ein-medikament-entsteht\/5-studien-mit-wenigen-kranken-phase-ii\/#primaryimage"},"image":{"@id":"https:\/\/biotechlerncenter.interpharma.ch\/themen\/wie-ein-medikament-entsteht\/5-studien-mit-wenigen-kranken-phase-ii\/#primaryimage"},"thumbnailUrl":"http:\/\/biotechlerncenter.interpharma.ch\/wp-content\/uploads\/sites\/4\/2020\/01\/istock_klinische-studie_900.jpg","datePublished":"2026-03-12T16:26:34+00:00","dateModified":"2026-03-13T17:14:09+00:00","breadcrumb":{"@id":"https:\/\/biotechlerncenter.interpharma.ch\/themen\/wie-ein-medikament-entsteht\/5-studien-mit-wenigen-kranken-phase-ii\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/biotechlerncenter.interpharma.ch\/themen\/wie-ein-medikament-entsteht\/5-studien-mit-wenigen-kranken-phase-ii\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/biotechlerncenter.interpharma.ch\/themen\/wie-ein-medikament-entsteht\/5-studien-mit-wenigen-kranken-phase-ii\/#primaryimage","url":"http:\/\/biotechlerncenter.interpharma.ch\/wp-content\/uploads\/sites\/4\/2020\/01\/istock_klinische-studie_900.jpg","contentUrl":"http:\/\/biotechlerncenter.interpharma.ch\/wp-content\/uploads\/sites\/4\/2020\/01\/istock_klinische-studie_900.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/biotechlerncenter.interpharma.ch\/themen\/wie-ein-medikament-entsteht\/5-studien-mit-wenigen-kranken-phase-ii\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/"},{"@type":"ListItem","position":2,"name":"Sujets","item":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/sujets\/"},{"@type":"ListItem","position":3,"name":"Gen\u00e8se d&rsquo;un m\u00e9dicament","item":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/sujets\/genese-dun-medicament\/"},{"@type":"ListItem","position":4,"name":"5. Des \u00e9tudes portant sur quelques malades: phase II"}]},{"@type":"WebSite","@id":"https:\/\/biotechlerncenter.interpharma.ch\/#website","url":"https:\/\/biotechlerncenter.interpharma.ch\/","name":"biotechlerncenter","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/biotechlerncenter.interpharma.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/wp-json\/wp\/v2\/pages\/870","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/wp-json\/wp\/v2\/comments?post=870"}],"version-history":[{"count":3,"href":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/wp-json\/wp\/v2\/pages\/870\/revisions"}],"predecessor-version":[{"id":3212,"href":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/wp-json\/wp\/v2\/pages\/870\/revisions\/3212"}],"up":[{"embeddable":true,"href":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/wp-json\/wp\/v2\/pages\/898"}],"wp:attachment":[{"href":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/wp-json\/wp\/v2\/media?parent=870"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}